Free shipping on all orders over $ 500

Avitinib (AC0010)

Cat. No. M10337

All AbMole products are for research use only, cannot be used for human consumption.

Avitinib (AC0010) Structure
Synonym:

Abivertinib; AC-0010

Size Price Availability Quantity
5mg USD 87 In stock
10mg USD 133 In stock
25mg USD 263 In stock
100mg USD 633 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Avitinib (Abivertinib; AC0010) is a third-generation irreversible EGFR tyrosine kinase inhibitor, with potential antineoplastic activity. Avitinib (Abivertinib; AC0010) inhibits cell proliferation, reduces colony-forming capacity, and induces apoptosis and cell cycle arrest in AML cells, especially those harboring FLT3-ITD mutations. 

In vivo, AC0010 (500 mg/kg; oral) administration daily resulted in complete remission of tumors with EGFR active and T790M mutations for over 143 days with no weight loss in a xenografte model.

Chemical Information
Molecular Weight 487.53
Formula C26H26FN7O2
CAS Number 1557267-42-1
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Shujuan Huang, et al. J Cancer. Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro

[2] Shujuan Huang, et al. Cancer Lett. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia

[3] Hanping Wang, et al. Lung Cancer. Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation

Related EGFR/HER2 Products
Panitumumab

Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR).

Nimotuzumab

Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR.

Matuzumab

Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR.

AEE788

AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.

Sapitinib (AZD8931)

AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Avitinib (AC0010), Abivertinib; AC-0010 supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.